Toll-like receptor 9 in breast cancer

Frontiers in Immunology

Volumn 5, Issue JUL, 2014, Pages

  Sandholm, Jouko ^a,b   Selander, Katri S ^c,d,e  

^a TURKU CENTRE FOR BIOTECHNOLOGY   (Finland)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

^c LAPLAND CENTRAL HOSPITAL   (Finland)

^d Heerskink School of Medicine   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Breast cancer; Inflammation; Invasion; Prognosis; Tlr9

Indexed keywords

EID: 84905650695     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00330     Document Type: Review

References (88)

1. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A toll-like receptor recognizes bacterial DNA. Nature (2000) 408:740-5. doi: 10.1038/35047123
2. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett (2003) 85:85-95. doi:10.1016/S0165-2478(02)00228-6
3. Bamboat ZM, Balachandran VP, Ocuin LM, Obaid H, Plitas G, DeMatteo RP. Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury. Hepatology (2010) 51:621-32. doi:10.1002/hep.23365
4. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev (2005) 204:27-42. doi:10.1111/j.0105-2896.2005.00239.x
5. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, et al. Nucleic acids of mammalian origin can act as endogenous ligands for toll-like receptors and may promote systemic lupus erythematosus. J Exp Med (2005) 202:1131-9. doi:10.1084/jem.20050914
6. Bauer S, Kirschning CJ, Häcker H, Redecke V, Hausmann S, Akira S, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A (2001) 98:9237-42. doi:10.1073/pnas.161293498
7. Suwarti S, Yamazaki T, Svetlana C, Hanagata N. Recognition of CpG oligodeoxynucleotides by human toll-like receptor 9 and subsequent cytokine induction. Biochem Biophys Res Commun (2013) 430:1234-9. doi:10.1016/j.bbrc.2012.12.068
8. Haas T, Schmitz F, Heit A, Wagner H. Sequence independent interferon-alpha induction by multimerized phosphodiester DNA depends on spatial regulation of toll-like receptor-9 activation in plasmacytoid dendritic cells. Immunology (2009) 126:290-8. doi:10.1111/j.1365-2567.2008.02897.x
9. Leifer CA, Kennedy MN, Mazzoni A, Lee C, Kruhlak MJ, Segal DM. TLR9 is localized in the endoplasmic reticulum prior to stimulation. J Immunol (2004) 173:1179-83. doi:10.4049/jimmunol.173.2.1179
10. Hidmark A, von Saint Paul A, Dalpke AH. Cutting edge: TLR13 is a receptor for bacterial RNA. J Immunol (2012) 189(6):2717-21. doi:10.4049/jimmunol.1200898
11. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol (2004) 5:190-8. doi:10.1038/ni1028
12. Bauer S. Toll-like receptor 9 processing: the key event in toll-like receptor 9 activation? Immunol Lett (2013) 149:85-7. doi:10.1016/j.imlet.2012.11.003
13. Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity (2010) 32:305-15. doi:10.1016/j.immuni.2010.03.012
14. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol (2008) 8:594-606. doi:10.1038/nri2358
15. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol (2001) 2:675-80. doi:10.1038/90609
16. Hoque R, Malik AF, Gorelick F, Mehal WZ. Sterile inflammatory response in acute pancreatitis. Pancreas (2012) 41:353-7. doi:10.1097/MPA.0b013e3182321500
17. Huang H, Evankovich J, Yan W, Nace G, Zhang L, Ross M, et al. Endogenous histones function as alarmins in sterile inflammatory liver injury through toll-like receptor 9 in mice. Hepatology (2011) 54:999-1008. doi:10.1002/hep.24501
18. Imaeda AB, Watanabe A, Sohail MA, Mahmood S, Mohamadnejad M, Sutterwala FS, et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest (2009) 119:305-14. doi:10.1172/JCI35958
19. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol (2008) 8:279-89. doi:10.1038/nri2215
20. Coban C, Ishii KJ, Kawai T, Hemmi H, Sato S, Uematsu S, et al. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med (2005) 201:19-25. doi:10.1084/jem.20041836
21. Parroche P, Lauw FN, Goutagny N, Latz E, Monks BG, Visintin A, et al. Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to toll-like receptor 9. Proc Natl Acad Sci U S A (2007) 104:1919-24. doi:10.1073/pnas.0608745104
22. Wagner H. Hemozoin: malaria's "built-in" adjuvant and TLR9 agonist. Cell Host Microbe (2010) 7:5-6. doi:10.1016/j.chom.2010.01.002
23. Rigby RE, Webb LM, Mackenzie KJ, Li Y, Leitch A, Reijns MA, et al. RNA:DNA hybrids are a novel molecular pattern sensed by TLR9. EMBO J (2014) 33:542-58. doi:10.1002/embj.201386117
24. Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res (2006) 4:437-47. doi:10.1158/1541-7786.MCR-06-0007
25. Armogida SA, Yannaras NM, Melton AL, Srivastava MD. Identification and quantification of innate immune system mediators in human breast milk. Allergy Asthma Proc (2004) 25:297-304.
26. Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler W, et al. Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci (2010) 101:1059-66. doi:10.1111/j.1349-7006.2010.01491.x
27. Väisänen MR, Väisänen T, Jukkola-Vuorinen A, Vuopala KS, Desmond R, Selander KS, et al. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors. Prostate (2010) 70:817-24. doi:10.1002/pros.21115
28. Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW, et al. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate (2007) 67:774-81. doi:10.1002/pros.20562
29. Jukkola-Vuorinen A, Rahko E, Vuopala KS, Desmond R, Lehenkari PP, Harris KW, et al. Toll-like receptor-9 expression is inversely correlated with estrogen receptor status in breast cancer. J Innate Immun (2008) 1:59-68. doi:10.1159/000151602
30. Ronkainen H, Hirvikoski P, Kauppila S, Vuopala KS, Paavonen TK, Selander KS, et al. Absent toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma. J Exp Clin Cancer Res (2011) 30:84. doi:10.1186/1756-9966-30-84
31. Takala H, Kauppila JH, Soini Y, Selander KS, Vuopala KS, Lehenkari PP, et al. Toll-like receptor 9 is a novel biomarker for esophageal squamous cell dysplasia and squamous cell carcinoma progression. J Innate Immun (2011) 3:631-8. doi:10.1159/000329115
32. Tuomela J, Sandholm J, Karihtala P, Ilvesaro J, Vuopala KS, Kauppila JH, et al. Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer. Breast Cancer Res Treat (2012) 135:481-93. doi:10.1007/s10549-012-2181-7
33. Väisänen MR, Jukkola-Vuorinen A, Vuopala KS, Selander KS, Vaarala MH. Expression of toll-like receptor-9 is associated with poor progression-free survival in prostate cancer. Oncol Lett (2013) 5:1659-63.
34. González-Reyes S, Marín L, González L, González LO, del CasarJM, Lamelas ML, et al. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer (2010) 10:665. doi:10.1186/1471-2407-10-665
35. Ilvesaro JM, Merrell MA, Li L, Wakchoure S, Graves D, Brooks S, et al. Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion. Mol Cancer Res (2008) 6:1534-43. doi:10.1158/1541-7786.MCR-07-2005
36. Sandholm J, Kauppila JH, Pressey C, Tuomela J, Jukkola-Vuorinen A, Vaarala M, et al. Estrogen receptor-alpha and sex steroid hormones regulate toll-like receptor-9 expression and invasive function in human breast cancer cells. Breast Cancer Res Treat (2012) 132:411-9. doi:10.1007/s10549-011-1590-3
37. McKelvey KJ, Highton J, Hessian PA. Cell-specific expression of TLR9 isoforms in inflammation. J Autoimmun (2011) 36(1):76-86. doi:10.1016/j.jaut.2010.11.001
38. Wang C, Cao S, Yan Y, Ying Q, Jiang T, Xu K, et al. TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients. BMC Cancer (2010) 10:415. doi:10.1186/1471-2407-10-415
39. Kauppila JH, Takala H, Selander KS, Lehenkari PP, Saarnio J, Karttunen TJ. Increased toll-like receptor 9 expression indicates adverse prognosis in oesophageal adenocarcinoma. Histopathology (2011) 59:643-9. doi:10.1111/j.1365-2559.2011.03991.x
40. Coch C, Busch N, Wimmenauer V, Hartmann E, Janke M, Abdel-Mottaleb MM, et al. Higher activation of TLR9 in plasmacytoid dendritic cells by microbial DNA compared with self-DNA based on CpG-specific recognition of phosphodiester DNA. J Leukoc Biol (2009) 86:663-70. doi:10.1189/jlb.0509314
41. Qiao B, Li B, Yang X, Zhang H, Chu Y, Wang Y, et al. Specific siRNA downregulated TLR9 and altered cytokine expression pattern in macrophage after CpG DNA stimulation. Cell Mol Immunol (2005) 2:130-5.
42. Lahoud MH, Ahmet F, Zhang JG, Meuter S, Policheni AN, Kitsoulis S, et al. DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc Natl Acad Sci U S A (2012) 109:16270-5. doi:10.1073/pnas.1208796109
43. Kauppila JH, Karttunen TJ, Saarnio J, Nyberg P, Salo T, Graves DE, et al. Short DNA sequences and bacterial DNA induce esophageal, gastric, and colorectal cancer cell invasion. APMIS (2013) 121:511-22. doi:10.1111/apm.12016
44. Nurmenniemi S, Kuvaja P, Lehtonen S, Tiuraniemi S, Alahuhta I, Mattila RK, et al. Toll-like receptor 9 ligands enhance mesenchymal stem cell invasion and expression of matrix metalloprotease-13. Exp Cell Res (2010) 316:2676-82. doi:10.1016/j.yexcr.2010.05.024
45. Jozsef L, Khreiss T, El Kebir D, Filep JG. Activation of TLR-9 induces IL-8 secretion through peroxynitrite signaling in human neutrophils. J Immunol (2006) 176:1195-202. doi:10.4049/jimmunol.176.2.1195
46. Peter M, Bode K, Lipford GB, Eberle F, Heeg K, Dalpke AH. Characterization of suppressive oligodeoxynucleotides that inhibit toll-like receptor-9-mediated activation of innate immunity. Immunology (2008) 123:118-28. doi:10.1111/j.1365-2567.2007.02718.x
47. Tuomela J, Sandholm J, Kaakinen M, Patel A, Kauppila JH, Ilvesaro J, et al. DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells. Breast Cancer Res Treat (2013) 142:477-87. doi:10.1007/s10549-013-2762-0
48. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature (2007) 449:564-9. doi:10.1038/nature06116
49. Weber G, Chamorro CI, Granath F, Liljegren A, Zreika S, Saidak Z, et al. Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer. Breast Cancer Res (2009) 11:R6. doi:10.1186/bcr2221
50. Heilborn JD, Nilsson MF, Jimenez CI, Sandstedt B, Borregaard N, Tham E, et al. Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. Int J Cancer (2005) 114:713-9. doi:10.1002/ijc.20795
51. Kuhlicke J, Frick JS, Morote-Garcia JC, Rosenberger P, Eltzschig HK. Hypoxia inducible factor (HIF)-1 coordinates induction of toll-like receptors TLR2 and TLR6 during hypoxia. PLoS One (2007) 2:e1364. doi:10.1371/journal.pone.0001364
52. Oka T, Hikoso S, Yamaguchi O, Taneike M, Takeda T, Tamai T, et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature (2012) 485:251-5. doi:10.1038/nature10992
53. Sandholm J, Tuomela J, Kauppila JH, Harris KW, Graves D, Selander KS. Hypoxia regulates toll-like receptor-9 expression and invasive function in human brain cancer cells in vitro. Oncol Lett (2014) 8(1):266-74.
54. De Nardo D, De Nardo CM, Nguyen T, Hamilton JA, Scholz GM. Signaling crosstalk during sequential TLR4 and TLR9 activation amplifies the inflammatory response of mouse macrophages. J Immunol (2009) 183:8110-8. doi:10.4049/jimmunol.0901031
55. Krieg AM. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther (2012) 22:77-89. doi:10.1089/nat.2012.0340
56. Xiong Z, Gharagozlou S, Vengco I, Chen W, Ohlfest JR. Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis. Clin Cancer Res (2008) 14:5484-93. doi:10.1158/1078-0432.CCR-07-4139
57. Cai Q, Kublo L, Cumberland R, Gooding W, Baar J. Optimized systemic dosing with CpG DNA enhances dendritic cell-mediated rejection of a poorly immunogenic mammary tumor in BALB/c mice. Clin Transl Sci (2009) 2:62-6. doi:10.1111/j.1752-8062.2008.00073.x
58. Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E. Peptide vaccine given with a toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res (2007) 67:1326-34. doi:10.1158/0008-5472.CAN-06-3290
59. Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R. Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther (2006) 5:2106-14. doi:10.1158/1535-7163.MCT-06-0158
60. Yang L, Wu X, Wan M, Yu Y, Yu Y, Wang L. CpG oligodeoxynucleotides with double stem-loops show strong immunostimulatory activity. Int Immunopharmacol (2013) 15:89-96. doi:10.1016/j.intimp.2012.10.020
61. Yu D, Zhu FG, Bhagat L, Wang H, Kandimalla ER, Zhang R, et al. Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem Biophys Res Commun (2002) 297:83-90. doi:10.1016/S0006-291X(02)02127-7
62. Hurtado P, Peh CA. LL-37 promotes rapid sensing of CpG oligodeoxynucleotides by B lymphocytes and plasmacytoid dendritic cells. J Immunol (2010) 184:1425-35. doi:10.4049/jimmunol.0902305
63. de la Cruz-Merino L, Barco-Sánchez A, Henao Carrasco F, Nogales Fernández E, Vallejo Benítez A, Brugal Molina J, et al. New insights into the role of the immune microenvironment in breast carcinoma. Clin Dev Immunol (2013) 2013:785317. doi:10.1155/2013/785317
64. Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol (2007) 178:3186-97. doi:10.4049/jimmunol.178.5.3186
65. Fathallah I, Parroche P, Gruffat H, Zannetti C, Johansson H, Yue J, et al. EBV latent membrane protein 1 is a negative regulator of TLR9. J Immunol (2010) 185:6439-47. doi:10.4049/jimmunol.0903459
66. Vincent IE, Zannetti C, Lucifora J, Norder H, Protzer U, Hainaut P, et al. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One (2011) 6:e26315. doi:10.1371/journal.pone.0026315
67. Sajadi SM, Mirzaei V, Hassanshahi G, Khorramdelazad H, Daredor HY, Hosseini SM, et al. Decreased expressions of toll-like receptor 9 and its signaling molecules in chronic hepatitis B virus-infected patients. Arch Pathol Lab Med (2013) 137:1674-9. doi:10.5858/arpa.2012-0415-OA
68. Shahzad N, Shuda M, Gheit T, Kwun HJ, Cornet I, Saidj D, et al. The T antigen locus of Merkel cell polyomavirus downregulates human toll-like receptor 9 expression. J Virol (2013) 87:13009-19. doi:10.1128/JVI.01786-13
69. Hasan UA, Zannetti C, Parroche P, Goutagny N, Malfroy M, Roblot G, et al. The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the toll-like receptor 9 promoter. J Exp Med (2013) 210:1369-87. doi:10.1084/jem.20122394
70. van Gent M, Griffin BD, Berkhoff EG, van Leeuwen D, Boer IG, Buisson M, et al. EBV lytic-phase protein BGLF5 contributes to TLR9 downregulation during productive infection. J Immunol (2011) 186:1694-702. doi:10.4049/jimmunol.0903120
71. Xu N, Yao HP, Lv GC, Chen Z. Downregulation of TLR7/9 leads to deficient production of IFN-alpha from plasmacytoid dendritic cells in chronic hepatitis B. Inflamm Res (2012) 61:997-1004. doi:10.1007/s00011-012-0493-z
72. Hasimu A, Ge L, Li QZ, Zhang RP, Guo X. Expressions of toll-like receptors 3, 4, 7, and 9 in cervical lesions and their correlation with HPV16 infection in Uighur women. Chin J Cancer (2011) 30:344-50. doi:10.5732/cjc.010.10456
73. Lagunes-Servin H, Torres J, Maldonado-Bernal C, Pérez-Rodríguez M, Huerta-Yépez S, Madrazo de la Garza A, et al. Toll-like receptors and cytokines are upregulated during Helicobacter pylori infection in children. Helicobacter (2013) 18:423-32. doi:10.1111/hel.12067
74. Buehring GC, Shen HM, Jensen HM, Choi KY, Sun D, Nuovo G. Bovine leukemia virus DNA in human breast tissue. Emerg Infect Dis (2014) 20:772-82. doi:10.3201/eid2005.131298
75. Lv YR, Wang JL, Zhang K, Gao HD, Sun JZ, Gong YY, et al. Human papilloma viruses (HPVs) no co-existence in breast cancer and cervical cells in the same patient. Chin J Physiol (2014) 57(2):105-6. doi:10.4077/CJP.2014.BAC207
76. Manzouri L, Salehi R, Shariatpanahi S, Rezaie P. Prevalence of human papilloma virus among women with breast cancer since 2005-2009 in Isfahan. Adv Biomed Res (2014) 3:75. doi:10.4103/2277-9175.125873
77. Alibek K, Kakpenova A, Mussabekova A, Sypabekova M, Karatayeva N. Role of viruses in the development of breast cancer. Infect Agent Cancer (2013) 8:32. doi:10.1186/1750-9378-8-32
78. Kim SY, Choi YJ, Joung SM, Lee BH, Jung YS, Lee JY. Hypoxic stress up-regulates the expression of toll-like receptor 4 in macrophages via hypoxia-inducible factor. Immunology (2010) 129:516-24. doi:10.1111/j.1365-2567.2009.03203.x
79. Piccolo S, Enzo E, Montagner M. p63, Sharp1, and HIFs: master regulators of metastasis in triple-negative breast cancer. Cancer Res (2013) 73:4978-81. doi:10.1158/0008-5472.CAN-13-0962
80. Silver AC, Arjona A, Walker WE, Fikrig E. The circadian clock controls toll-like receptor 9-mediated innate and adaptive immunity. Immunity (2012) 36:251-61. doi:10.1016/j.immuni.2011.12.017
81. Fioretti FM, Sita-Lumsden A, Bevan CL, Brooke G. Revising the role of the androgen receptor in breast cancer. J Mol Endocrinol (2014) 52(3):R257-65. doi:10.1530/JME-14-0030
82. Du X, Poltorak A, Wei Y, Beutler B. Three novel mammalian toll-like receptors: gene structure, expression, and evolution. Eur Cytokine Netw (2000) 11:362-71.
83. Torres-García D, Cruz-Lagunas A, García-Sancho Figueroa MC, Fernández-Plata R, Baez-Saldaña R, Mendoza-Milla C, et al. Variants in toll-like receptor 9 gene influence susceptibility to tuberculosis in a Mexican population. J Transl Med (2013) 11:220. doi:10.1186/1479-5876-11-220
84. Zhang J, Zhu Q, Meng F, Lei H, Zhao Y. Association study of TLR-9 polymorphisms and systemic lupus erythematosus in northern Chinese Han population. Gene (2014) 533:385-8. doi:10.1016/j.gene.2013.08.051
85. Laska MJ, Troldborg A, Hansen B, Stengaard-Pedersen K, Junker P, Nexø BA, et al. Polymorphisms within toll-like receptors are associated with systemic lupus erythematosus in a cohort of Danish females. Rheumatology (Oxford) (2014) 53:48-55. doi:10.1093/rheumatology/ket316
86. Wang X, Xue L, Yang Y, Xu L, Zhang G. TLR9 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. PLoS One (2013) 8:e65731. doi:10.1371/journal.pone.0065731
87. Resler AJ, Malone KE, Johnson LG, Malkki M, Petersdorf EW, McKnight B, et al. Genetic variation in TLR or NFkappaB pathways and the risk of breast cancer: a case-control study. BMC Cancer (2013) 13:219. doi:10.1186/1471-2407-13-219
88. Etokebe GE, Knezevic J, Petricevic B, Pavelic J, Vrbanec D, Dembic Z. Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in case-control study with breast cancer. Genet Test Mol Biomarkers (2009) 13:729-34. doi:10.1089/gtmb.2009.0045